SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 4, 2019
BioMarin Pharmaceutical Inc.
(Exact name of Registrant as Specified in Its Charter)
Delaware | 000-26727 | 68-0397820 | ||
(State or Other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.) | ||
770 Lindaro Street, San Rafael, California | 94901 | |||
(Address of Principal Executive Offices) | (Zip Code) |
Registrant’s Telephone Number, Including Area Code: (415)506-6700
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ | Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ | Soliciting material pursuant to Rule14a-12 under the Exchange Act (17 CFR240.14a-12) |
☐ | Pre-commencement communication pursuant to Rule14d-2(b) under the Exchange Act (17 CFR240.14d-2(b)) |
☐ | Pre-commencement communication pursuant to Rule13e-4(c) under the Exchange Act (17 CFR240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
Common Stock, $.001 par value | BMRN | The Nasdaq Global Select Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule12b-2 of the Securities Exchange Act of 1934 (17 CFR§240.12b-2).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02 | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
On June 4, 2019, BioMarin Pharmaceutical Inc. (“BioMarin”) held its 2019 Annual Meeting of Stockholders (the “Annual Meeting”). At the Annual Meeting, BioMarin’s stockholders approved (i) an amendment to the BioMarin Pharmaceutical Inc. 2017 Equity Incentive Plan (the “2017 Plan”) to increase the number of shares of BioMarin common stock reserved for issuance thereunder by 11,000,000 shares (the “2017 Plan Amendment”) and (ii) amendments to the BioMarin Pharmaceutical Inc. Amended and Restated 2006 Employee Stock Purchase Plan (the “ESPP”) to (a) increase the number of shares of common stock reserved for issuance thereunder by 3,500,000 shares, (b) extend the term of the ESPP such that it may continue with respect to new offerings until terminated by BioMarin’s Board of Directors (the “Board”) and (c) make other administrative changes (including the definition of eligible employees, changes to the enrollment and withdrawal processes, clarification of fair market value determination for overlapping offering periods, and delegation of powers to the administrator related toNon-United States Offerings) (collectively, the “ESPP Amendments”).
The 2017 Plan Amendment and ESPP Amendments previously had been approved, subject to stockholder approval, by the Compensation Committee of BioMarin’s Board. The 2017 Plan Amendment and ESPP Amendments became effective immediately upon stockholder approval at the Annual Meeting.
More detailed summaries of the material features of the 2017 Plan Amendment and ESPP Amendments are set forth in BioMarin’s definitive proxy statement for the Annual Meeting filed with the Securities and Exchange Commission on April 23, 2019 (the “Proxy Statement”) under the headings “PROPOSAL NO. FOUR: Approval of an Amendment to the 2017 Equity Incentive Plan” and “PROPOSAL NO. FIVE: Approval of Amendments to the Amended and Restated 2006 Employee Stock Purchase Plan,” respectively. Those summaries and the foregoing descriptions are qualified in their entirety by reference to the full text of the 2017 Plan, as amended and the ESPP, as amended, which are attached to the Proxy Statement as Appendix A and Appendix B, respectively.
Item 5.07 | Submission of Matters to a Vote of Security Holders. |
A total of 179,052,949 shares of common stock were entitled to vote as of April 8, 2019, the record date for the Annual Meeting. There were 158,025,941 shares of common stock present in person or represented by proxy at the Annual Meeting, at which the stockholders were asked to vote on five proposals, each of which is described in more detail in the Proxy Statement. Set forth below are the matters acted upon by the stockholders, and the final voting results of each such proposal.
Proposal No. 1: Election of Directors
Directors Elected | Vote For | Withheld | Broker Non-Votes | |||
Jean-Jacques Bienaimé | 144,289,763 | 4,909,388 | 8,826,790 | |||
Willard Dere, M.D. | 136,620,674 | 12,578,477 | 8,826,790 | |||
Michael Grey | 145,315,942 | 3,883,209 | 8,826,790 | |||
Elaine J. Heron, Ph.D. | 131,191,744 | 18,007,407 | 8,826,790 | |||
Robert J. Hombach | 148,939,454 | 259,697 | 8,826,790 | |||
V. Bryan Lawlis, Ph.D. | 88,058,817 | 61,140,334 | 8,826,790 | |||
Alan J. Lewis, Ph.D. | 146,234,077 | 2,965,074 | 8,826,790 | |||
Richard A. Meier | 144,117,377 | 5,081,774 | 8,826,790 | |||
David Pyott, M.D. (Hon.) | 136,051,065 | 13,148,086 | 8,826,790 | |||
Dennis J. Slamon, M.D., Ph.D. | 136,643,862 | 12,555,289 | 8,826,790 |
Based on the votes set forth above, BioMarin’s stockholders elected each of the ten nominees set forth above to serve as a director of BioMarin until the next annual meeting of stockholders and until his or her successor is duly elected and qualified, or, if sooner, until the director’s death, resignation or removal.
Proposal No. 2: Ratification of the Selection of Independent Registered Public Accounting Firm
The ratification of the selection of KPMG LLP as BioMarin’s independent registered public accounting firm for the fiscal year ending December 31, 2019, as set forth in the Proxy Statement, received the following votes:
For | Against | Abstain | ||
157,114,131 | 688,565 | 223,245 |
- 2 -
Based on the votes set forth above, BioMarin’s stockholders ratified the selection of KPMG LLP as BioMarin’s independent registered public accounting firm to serve for the year ending December 31, 2019.
Proposal No. 3: Advisory Vote on the Compensation of BioMarin’s Named Executive Officers
The advisory(non-binding) vote to approve the compensation of BioMarin’s named executive officers, as set forth in the Proxy Statement, received the following votes:
For | Against | Abstain | Broker | |||
123,828,624 | 25,272,518 | 98,009 | 8,826,790 |
Based on the votes set forth above, BioMarin’s stockholders approved, on an advisory basis, the compensation of BioMarin’s named executive officers, as set forth in the Proxy Statement.
Proposal No. 4: Approval of an Amendment to the BioMarin 2017 Equity Incentive Plan
The approval of the 2017 Plan Amendment, as set forth in the Proxy Statement, received the following votes:
For | Against | Abstain | Broker | |||
122,419,176 | 26,680,818 | 99,157 | 8,826,790 |
Based on the votes set forth above, BioMarin’s stockholders approved the 2017 Plan Amendment, as set forth in the Proxy Statement.
Proposal No. 5: Approval of Amendments to the BioMarin Amended and Restated 2006 Employee Stock Purchase Plan
The approval of the ESPP Amendments, as set forth in the Proxy Statement, received the following votes:
For | Against | Abstain | Broker | |||
148,843,102 | 278,721 | 77,328 | 8,826,790 |
Based on the votes set forth above, BioMarin’s stockholders approved the ESPP Amendments.
- 3 -
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
BioMarin Pharmaceutical Inc., a Delaware corporation | ||||||
Date: June 7, 2019 | By: | /s/ G. Eric Davis | ||||
G. Eric Davis Executive Vice President, General Counsel |
- 4 -